Demand for wireless charging is witnessing significant increase owing to rising consumer awareness as more number of mobile devices are being launched with embedded wireless charging technology.

Albany, NY -- (SBWIRE) -- 12/27/2017 -- The presence of a large pool of participants, such as Qualcomm Technologies, Texas Instruments, Energized Holdings, Leggett & Platt, Integrated Device Technology, ConvenientPower HK, WiTricity Corp., Powermat Technologies, and PowerbyPoxi, points towards a fragmented and a highly competitive structure of the global market for wireless charging, states a research report by Persistence Market Research (PMR).

These participants are concentrating on innovation and technological advancements of their products in order to meet the demand of their consumers. Going forward, they are projected to shift their focus towards mergers, acquisitions, and alliances in an effort to expand their consumer base across various regions in the near future.

Researchers expect the rivalry between the key participants to intensify in the years to come. The global market for wireless charging is expected to progress at an exceptional CAGR of 34% over the period from 2016 to 2024 and increase to US$2.6 bn by the end of the period of the forecast, notes the research study.

Rising Penetration of Mobile Devices to Boost Market's Growth

"The rising penetration of mobile devices is the key factor behind the significant growth of the global wireless charging market," says an analyst at PMR. Including embedded wireless charging technology, the technological advancements in mobile devices are influencing the demand for wireless charging solutions remarkably across the world, while creasing awareness among consumers regarding this technology.

The rising number of mobile device manufacturers and vendors, globally, are integrating the wireless charging feature in their high-end smartphone modals, notebooks, laptops, and wearable devices, which is propelling the uptake of this technology. This, as a result, is likely to boost this market in the years to come. Apart from this, the ongoing expansion in the electric vehicle market is also projected to support this market over the next few years.

On the other hand, the manufacturers of wireless charging solutions may face difficulty in finding the suitable charging technology in the years to come due to the uncertainty over the expansion of their product portfolios, since they keep on hovering around the selection of appropriate charging technology to ensure the compatibility with all the electronic devices available across the world, states the research report.

View Report Table of Contents, Figures, and Tables

Presence of Technologically Advanced IT Infrastructure to Ensure North America's Dominance

Geographically, the global market for wireless charging registers its presence into Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. Thanks to t a large population base and the high number of mobile device users, Asia Pacific has emerged as the leading geographical segment of this market. The regional market is projected to retain its leadership throughout the forecast period on the ground of the heavy investments of leading companies in the emerging economies, especially, China, South Korea, and India.

Amongst other regional markets, Europe and North America are likely to register a steady surge in their respective markets for wireless charging over the years to come. North America is expected to gain from the presence of an advanced IT infrastructure, whereas, Europe will benefit from the large number of established companies headquartered in this region, notes the research report.

Request Report for TOC @ https://www.persistencemarketresearch.com/market-research/wireless-charging-market/toc

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The pediatric vaccines segment dominates the global pediatric vaccine products market.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Lately, the global pediatric vaccination market has been exhibiting a robust growth. The rise in initiatives by various governments to spread awareness regarding child healthcare, coupled with increasing investments, is propelling the global market to a significant extent. Various upcoming child healthcare programs by UNICEF and the WHO are likely to boost this market in the near future.

The worldwide pediatric vaccine market is broadly analyzed on three fronts: products, technology, and types of diseases. The markets for CNS drugs, pediatric vaccines, pediatric hormones, anti-infective drugs, and allergy and respiratory drugs are the major segments of the global pediatric vaccines products market. On the basis of technology, this market is classified into live attenuated vaccines, dendritic cells vaccines, synthetic vaccines, inactivated vaccines, toxoid vaccines, conjugate vaccines, subunit vaccines, and recombinant vector vaccines. Infectious diseases, allergy, and cancer are the key segments of the pediatric vaccine market, based on the types of diseases. The market for infectious diseases is further divided into MMR, polio, pneumococcal disease, meningococcal disease, influenza, DTP, hepatitis, varicella, and rotavirus. North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for pediatric vaccines in the global arena.

Request Report TOC @ https://www.transparencymarketresearch.com/pulse-oximeters-market.html

This research report on the global pediatric vaccine market has been prepared after extensive research by experts at TMR. It presents a comprehensive analysis of this market on the basis of its current as well as historical performance. Growth drivers, restraints, and opportunities, along with prevalent trends and future prospects, have also been discussed at length in this report.

Overview of the Global Pediatric Vaccines Market

The global market for pediatric vaccines has reported an impressive development in its market valuation, thanks to the increasing rate of birth globally. The rising incidence of diseases such as polio, influenza, hepatitis has also fueled demand from the global pediatric vaccines market to a great extent.

The pediatric vaccines segment dominates the global pediatric vaccine products market. The market for live attenuated vaccines has registered the highest growth among all the segments, based on technology. By diseases, the infectious diseases segment has occupied the leading position at present. However, the rising prevalence of cancer, specifically Leukemia, in kids is projected to register the fastest growth in this market in the coming years. This will further boost the global market for pediatric vaccines in the near future.

North America leads the global market for pediatric vaccines and is closely followed by Europe. However, the market for pediatric vaccines in Asia Pacific is likely to report the fastest growth during the period from 2012 to 2018 owing to the high birth rate in China and India.

Though the growth prospects for the global market for pediatric vaccines looks lucrative, low accessibility to vaccines in developing economies, together with strict regulations for the usage of these vaccines, is likely to hamper the growth of this market over the next few years.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=404

Companies mentioned in the research report

GlaxoSmithKline is the leading vaccine manufacturer in the global pediatric vaccine market, thanks to its blockbuster influenza vaccines, Hiberix and Fluvarix

Other prominent players operating in worldwide market for pediatric vaccine are Pfizer, Merck, Sanofi Pasteur, Crucell, Janssen, Bharat Biotech, Kaketsuken, Panacea Biotec, Baxter, Zydus Cadila, Nuron, S K Chemicals, Dynavax Technologies, Serum Institute of India, Bharat Immunologicals and Biologicals, Lupin, Indian Immunologicals, Novartis, LG Life Sciences, Shenzhen Kangtai Biological Products, Sinovac Biotech, Bavarian Nordic, Bio Med, AstraZeneca, bioCSL, Valeant Pharmaceuticals, Takeda Pharmaceutical, and Mitsubishi Tanabe Pharma.

Pre Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=404

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The major geographies analyzed under this research study are North America, Asia-Pacific, Europe and Rest of the World.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Global Pulse Oximeters market is anticipated to grow significantly by year 2015 owing to the increasing penetration in alternate care market, adoption of low perfusion, motion tolerant technology, and increasing use in general care. Pulse Oximeters are used for measuring vital signs of patients as technology provides early warning for hypoxemia – a condition that indicates low arterial blood oxygen saturation level that may prove fatal. However, market is expected to gain momentum in the near future with continuous technological developments and growing implementations in the alternate care market. Introduction of pulse Oximeters with improved features is likely to accelerate the use of these devices in non critical settings, thus opening new opportunities for the market players.

Request Report TOC @ https://www.transparencymarketresearch.com/pulse-oximeters-market.html

This research report analyzes this market based on different market segments and major geographies. Report provides complete analysis of current market trends, industry growth drovers, restraints, market structure, and market projections for upcoming years. Report also includes analysis of technological improvements in this market, Porter's five force analysis, and detailed industry profiles of top market players. It includes review of micro and macro factors significant for existing market players and new entrants along with detailed value chain analysis.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=404

The major geographies analyzed under this research study are North America, Asia-Pacific, Europe and Rest of the World.

Some of the major players in this industry are CAS Medical Systems Inc., CareFusion Corporation, GE Healthcare UK Ltd., Masimo Corporation, Covidien Plc, Nihon-Kohden Corp, Nonin Medical Inc., Opto Circuits (India) Ltd., Criticare Systems Inc., Mediaid Inc., Spacelabs Healthcare Inc., Philips Healthcare, Welch Allyn Inc, and others.

Pre Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=404

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of several major drugs.

Partnerships, acquisitions, and collaborations with other leading companies for the development of newer products with improved efficacy are part of the growth strategies adopted by a number of players in the Kaposi sarcoma market. For instance, F. Hoffmann-La Roche Ltd launched a new Global Access Program in September 2014 in partnership with the Joint United Nations Program on HIV/AIDS, the President's Emergency Plan for AIDS Relief, the Clinton Health Access Initiative, and the Global Fund. The program was centered on HIV viral load testing.

Report Overview @ https://www.transparencymarketresearch.com/kaposis-sarcoma-market.html

High Incidence of HIV/AIDS, Organ Transplants Driving Growth of KS Market

Increased organ transplant procedures are a leading factor driving the Kaposi sarcoma market since the incidence of the cancer is high among patients who have undergone an organ transplant. "Organ transplant patients are given immunosuppressive agents to prevent their body from rejecting the graft. This makes them highly susceptible to Kaposi sarcoma associated herpesvirus (KSHV) infection," the author of the study explains. The long term use of these agents increases the rate of risk of these patients by more than 100 times compared to the general population.

The high incidence of HIV/AIDS associated Kaposi sarcoma is one of the major factors driving the adoption of HAART therapy, which subsequently fuels the overall KS market.

High Cost of Treatment a Major Drawback

The cost of cancer drugs used for the treatment of Kaposi sarcoma has been on the rise in the past few years, making it difficult for patients to seek treatment. This is a major concern for both the patients and the payers. "The prices of patented drugs have increased by over five times in the past few years in the U.S. and continue to rise," the TMR analyst comments. For instance, prices of major drugs used for the treatment of KS, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in combination with HAART, have been increasing significantly, making these unaffordable for middle and lower income groups.

Slow but Steady Growth in Store for Kaposi Sarcoma Market

The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.

By type of treatment, HAART led the overall Kaposi sarcoma market in terms of revenue, with chemotherapy and immunotherapy poised to register the highest growth rate over the coming years. In terms of region, the global Kaposi sarcoma market was led by North America in 2015 and the MEA region will record the fastest growth by 2024.

Request To Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354

Summary of Table of Content

1. Preface
2. Assumptions and Research Methodology
3. Executive Summary: Global Kaposi sarcoma market
4. Market Overview
5. Global Kaposi Sarcoma Market, by Treatment
6. Global Kaposi Sarcoma Market, by Distribution Channel
7. Global Kaposi Sarcoma Market, by Region
8. Global Kaposi Sarcoma Market, Pipeline Analysis
9. North America Kaposi Sarcoma Market
10. Europe Kaposi Sarcoma Market
11. Asia Pacific Kaposi Sarcoma Market
12. Latin America Kaposi Sarcoma Market
13. Middle East and Africa Kaposi Sarcoma Market
14. Global Kaposi Sarcoma Market Analysis, By Services
15. Competitive Landscape

Get Full Report Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=3354

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The market for physician dispensed cosmeceuticals has been undergoing a sea change with skincare specialist, dermatologists, and trichologists venturing into the market as entrepreneurs.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The global physician dispensed cosmeceuticals market features the presence of prominent names from the skincare and cosmetic industry. The market is currently undergoing a paradigm shift with a large pool of skincare specialists, dermatologists, and trichologists emerging as entrepreneurs, states Transparency Market Research (TMR) in a new study. However, the top three companies, L'Oreal S.A., Valeant Pharmaceuticals Inc., and Allergan plc, held more than 56% of the market in 2015. Of these, L'Oreal S.A. accounted for a larger share of 28% in the same year.

Since the physician dispensed cosmeceuticals market offers a plethora of products, it is important for manufacturers to cater to the consumer preference to gain a strong footing in the market. Product differentiation has therefore become a preferred strategy among competitors to enhance the marketability of their products. Even local manufacturers are focusing on advanced cosmeceuticals with a myriad of benefits to elevate rivalry.

Report Overview @ https://www.transparencymarketresearch.com/physician-dispensed-cosmeceuticals-market.html

Increased Sales Opportunities Expected as Dermatologists Venture into Cosmeceuticals Manufacturing

With dermatologists manufacturing cosmeceuticals alongside running their skincare centers, the market is expected to gain momentum in the forthcoming years. However, consumer apprehensions related to potential side effects associated with the use of cosmeceuticals may stand in the way of the market's growth. Besides this, the lack of awareness among customers regarding the revenue generating cosmeceuticals such as derma fillers and Botox is likely to create bottlenecks or the market in developing and under-developed countries. "Since the products offered in the market are highly sensitive to prevailing economic trends, financial downturns are also expected to have a negative impact on their sale," said a lead analyst at TMR.

"Nevertheless, the rising demand for branded cosmeceuticals due to their safety and efficacy is expected to boost opportunities for the market in the near future," he added. Furthermore, the knowledge about new skin conditions caused by exposure to pollution and climate changes will also boost sales of cosmeceuticals.

Among the products currently available in the market, the skincare products segment accounted for the leading market share in 2015. The increasing demand for cosmeceuticals across emerging economies and due to the rising geriatric population for treating various skin conditions will boost demand from this segment.

North America Exhibits Most Lucrative Opportunities for Cosmeceuticals Sale

Regionally, North America has been exhibiting the most lucrative prospects for the sales of cosmeceuticals. As per TMR, the regional market stood at US$4.7 bn in 2015 and is expected to reach US$10.52 by the end of 2024. If these valuations hold true, the physician dispensed cosmeceuticals market in North America will exhibit a CAGR of 9.6% between 2016 and 2024. However, TMR forecasts opportunities for the market in Asia Pacific to increase at the fastest CAGR. The Asia Pacific physician dispensed cosmeceuticals market is therefore expected to surge at a CAGR of 12.3% during the forecast period.

According to TMR, the global physician dispensed cosmeceuticals market stood at US$11.2 bn in 2015. Rising at a CAGR of 10.6% between 2016 and 2024, the market is expected to reach US$27.6 bn by 2024.

Request To Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=565

Summary of Table of Content

1. Preface
2. Executive Summary
3. Global Physician Dispensed Cosmeceuticals Market, (US$ Mn), 2014–2024
4. Global Physician Dispensed Cosmeceuticals Products Market: by Geography, (US$ Mn), 2014–2024
5. Company Profiles

Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=565

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

A wide range of testosterone replacement therapy (TRT) products containing different active ingredients have been made available by a large number of both global and local manufacturers.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Some of the key players in the global testosterone replacement therapy market include names such as Allergan Plc., AbbVie Inc., Bayer AG., Eli Lilly and Company, Endo Pharmaceuticals, Kyowa Kirin International Plc., Novartis AG., Mylan N.V., and Pfizer Inc. among others. The global market for testosterone replacement therapy is a little bit consolidate with the existence of a few big established companies and the presence of some domestic vendors that are playing their trade in the global market. Companies are now focusing on product development and innovation to enhance their market presence. Recently, Pfizer's new drug, Mylotarg, has been approved by the U.S. Food and Drug Administration, for certain patients who suffer from acute myeloid leukemia (AML). More and more companies are inclining towards getting their products sanctioned and get into the market. This will in turn, help in intensifying the competitive market landscape of the global testosterone replacement therapy market over the course of the given forecast period of 2016 to 2024. The top five companies in the global market held over 80% of the total market share in the 2015 out of which AbbVie Inc. has come up on top as the undisputed leader.

The global market is expected to reach an overall valuation of US$1.3 bn by the end of 2024. This valuation is lower than that found in the year of 2015 of US2.0 bn. The market will show a negative CAGR of -4.2% over the course of the forecast period of 2016 to 2024.

Report Overview @ https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html

Increasing Number of Hypogonadism Patients Drive Global Testosterone Replacement Therapy Market

Hypogonadism or more commonly known as the testosterone deficiency is a prevailing problem found in men that are aged between 40 to 79 years. Some studies also suggest that nearly 30% of the men across the globe are impacted by this testosterone deficiency problem. As the occurrence of such cases increase in number, the demand for testosterone replacement therapy is also expected soar subsequently.

Along with this major factor, another important driving factor for the growth of the global testosterone replacement therapy market is the increasing geriatric population across the world at a steady pace. This points to huge demographic target for the companies in the global testosterone replacement therapy market. It is expected that number of men reporting deficiency of testosterone will increase across the world as the number of older population will rise. In addition to these two factors, there is a growing awareness among the world population about the deficiency of testosterone and they are taking measures to tackle the problem. This will subsequently help in boosting the growth prospects of the global testosterone replacement therapy market.

Ill Effects of Testosterone Replacement Therapy May Impede Market Growth

However, there are some problems which are projected to cause some problems in the development of the global testosterone replacement therapy market. There is a modest level of apprehension among people about the side effects caused due to the use of the testosterone replacement therapy. Risk of developing metabolic and cardiovascular diseases is also impeding the growth of the market of testosterone replacement therapy products. There are several studies and reports which have indicated the ill effects of the therapy owing to which FDA has issued ample warnings about the possible risks. This has caused a large number of patients to see the testosterone replacement therapy in a negative shade of light.

In addition to this, the global market is nearing a cliff related to the patent approval issue. It is expected that the market for testosterone will face a problem of imminent expirations of patents and may lead to impeding the growth of the market in the coming years. However, with several drivers working in favor of the therapy, the market will witness a steady growth during the given forecast period of 2016 to 2024.

Request To Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

Summary of Table of Content
1. Preface
2. Executive Summary
3. Global Testosterone Replacement Therapy Market – Industry Analysis
4. North America Testosterone Replacement Therapy Market Analysis
5. Europe Testosterone Replacement Therapy Market Analysis
6. Asia Pacific Testosterone Replacement Therapy Market Analysis
7. Middle East and Africa (MEA) Testosterone Replacement Therapy Market Analysis
8. Latin America Testosterone Replacement Therapy Market Analysis
9. Global Testosterone Replacement Therapy Market, Country Snippets
10. Company Profiles

Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1097

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The soaring demand for sensors in homes and clinics for the treatment or diagnosis purpose is one of the primary factors augmenting the global market for disposable medical sensors.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The emergence of sensor technology and continuous advancements in the technology play a pivotal role in the growth of the global market for disposable medical sensors. Disposable medical sensors are available in various types, including implantable sensors, invasive sensors, and ingestible sensors. Implantable sensors are primarily used in medical research for measuring bodily parameters such as temperature, pressure, and force. Invasive sensors are used to detect chemical and physical parameters by inserting a chord or probe inside the human body. Injectable sensors are in form of pills and are swallowed for tracking health and functions inside the human body.

In terms of product, the global market for disposable medical sensors can be segmented into digital blood pressure meters, sleep apnea monitoring devices, peak flow meters, digital thermometers, spirometers, breath analyzers, and respiration pulse oximeters. Based on technology, the market can be divided into gas, pressure, temperature, acoustic, image, and flow sensors. The report encompasses all the vital aspects of the global disposable medical sensors market.

The soaring demand for sensors in homes and clinics for the treatment or diagnosis purpose is one of the primary factors augmenting the global market for disposable medical sensors. The rising incidence of chronic diseases, including cancer, cardiovascular, and kidney disorders along with growing prevalence of hospital-acquired infections are stoking the growth of the global market. Moreover, over the past few years, there has been a dramatic rise in the number of admissions to hospitals. This factor is translating into the greater uptake of disposable medical sensors. Besides, the increasing initiatives by governments worldwide, growing investments in the healthcare sector, and continuous improvements in the wearable technology are providing a fillip to the global market.

On the flip side, the lack of reimbursement policies is limiting the widespread adoption of disposable medical sensors. Furthermore, the changing regulatory guidelines for the manufacturing of these sensors are challenging the growth of the market. However, market players are expected to tap high unmet needs in emerging regions to maximize their revenue generation.

The key segments analyzed in the report on the basis of geography are Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America and Europe will account for a substantial cumulative share in the global arena during the forecast period. The growth of these regions is mainly driven by rapid advancements in the sensor technology and the presence of advanced and well-established healthcare information technology (HCIT) infrastructure. The domicile of a large number of key players provides an edge to these regions and ensure their fast pace growth.

Asia Pacific, on the other hand, will offer promising opportunities to global participants. The booming medical tourism industry, improving healthcare infrastructure, and rising consumer expenditure on healthcare are contributing to the growth of the region. The increasing consumer awareness is also impacting the APAC region positively.

Players in the global market for disposable medical sensors are putting in incessant efforts to improve their offerings in terms of safety, convenience, and sterility. Product innovation and launches are special areas of focus of the majority of players in the market to enhance their visibility. Several vendors are likely to follow the mergers and acquisitions path to improve their product portfolio. Some of the prominent companies in the global disposable medical sensors market are Measurement Specialties, Sensirion AG, ST Microelectronics, MEMSIC Inc., Smiths MedicalFreescale Semiconductor Inc., Philips Healthcare, GE Healthcare, Medtronic, Honeywell International Inc. Analog Devices Inc., and Coividien plc (Medtronic).

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=7679

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Epidermal Growth Factor Receptor (EGFR) Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The epidermal growth factor receptor (EGFR) is defined as a transmembrane tyrosine kinase receptor involved in the survival and proliferation of the cancerous cells. Any kind of mutations affecting these EFGR receptors or activity could results in cancer. Mutations lead to over-expresion resulting in large number of cancer, including lung cancer, anal cancer and glioblastoma multiforme. EGFR receptors are the first molecule target against which monoclonal antibodies (mAb) have been designed for cancer treatment. These monoclonal antibodies are sometimes also referred as EGFR antibodies. EGFR antibodies market can be segmented on the basis of the major antibodies which are used against EGFR receptors which include:

Cetuximab
Panitumumab
Nimotuzumab

Cetuximab (erbitux) and panitumumab (vecitibix) are the most preferred biosimilar EGFR antibodies which are used for treatment of cancer. These antibodies have demonstrated efficacy in the treatment of colorectal cancer as single agents and in combination with conventional chemotherapy. Since the US Food and Drug Administration (FDA) had approved cetuximab in 2003 and panitumumab in 2006, EGFR antibodies have become primary step of treatment algorithms for colorectal cancer. However, nimotuzumab is a humanized monoclonal antibody that as of 2014 is recognized under orphan drugs status in the U.S. and the European Union for the treatment of glioma. This drug has also achieved marketing approval in India and China for squamaus cell carcinoma of the neck and head, and is currently undergoing numerous clinical trials.

Additionally, many market players and research institutions are performing research activities on development of the biosuperior EGFR antibodies against cancerous cells. The most common biosuperior EGFR antibodies include engineered EGFR antibodies, Bi- and Multi-specific EGFR antibodies and EGFR antibody drug conjugates. As for instance, Hoffmann-La Roche is performing a phase 1b study of MPDL3280A (and engineered antibody) in combination with Tarceva in patients suffering from non-small cell lung cancer. Such extensive research and development activities associated with the development of EGFR antibodies biosuperiors is the major factor which is driving this market. However, the high cost associated with research activities and sunk cost involved in R&D activities restrains the EGFR antibodies market.

Moreover, the increasing incidence of cancer worldwide is also demanding for the more effective treatment methods, which is encouraging the researchers to develop EGFR antibodies. According to World Health Organization (WHO), cancer was the leading cause of death in 2012, accounting for 8.2 million deaths worldwide. Lung, liver, colorectal, stomach and breast cancers were responsible for most of the deaths every year. Statistics also revealed that breast cancer incidence had risen by more than 20% in 2012 from 2009, while breast cancer mortality rate has increased by 14%. Due to harsh lifestyle, excessive intake of alcohol and smoking habits, the incidence of cancer is increasing rapidly worldwide, especially in developed economies of North America and Europe. Increasing morbidity and mortality rate among the cancer patients is fuelling the demand for EGFR antibodies, hence driving the market.

Some of the market players which are actively contributing towards EGFR antibodies market include Amgen, Inc., Eisai, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer, Inc., Biocon Ltd., Takeda Pharmaceutical Company, Ltd. and Immunogen, Inc.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=7325

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The degree of competition in the global oligonucleotide synthesis market has intensified over the years on account of the foray of numerous new vendors.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Thermo Fisher Scientific, GE Healthcare, DNA Technologies, BioAutomation, Applied Biosystems, GeneDesign, Inc., Eurofins Genomics, Integrated Kaneka Eurogentec S.A., Sigma-Aldrich Corporation, and Agilent Technologies are some of the prominent participants in the global oligonucleotide synthesis market. Among them, Thermo Fisher Scientific is a dominant player that held maximum market share in 2016. Its leading position in the global oligonucleotide synthesis market is a result of its diverse product portfolio and strong outreach. Sigma-Aldrich Corporation comes in the second position in terms of market share.

The degree of competition in the global oligonucleotide synthesis market has intensified over the years on account of the foray of numerous new vendors. This has put a downward pressure on prices and consequently many leading vendors have had to cut down certain service and product arms in order to be able to focus on a niche sector.

A report by Transparency Market Research forecasts the global oligonucleotide synthesis market to rise at a CAGR of 11.2% between 2017 and 2025 to become worth US$1.65 bn in 2016 from US$4.189 bn by 2025.The different types of products in the global oligonucleotide synthesis market are equipment, reagents and consumables, and synthesized oligonucleotides. Of these, the synthesized oligonucleotides segment accounts for a leading share in the market. This is because synthesized oligonucleotides are ready to use oligonucleotides that find widespread application in research, therapeutic, and diagnostics. These are also available as customized oligos prepared as per need.

Depending upon geography, the key segments of the global oligonucleotide synthesis market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Currently, North America leads the global oligonucleotide synthesis market vis-a-vis value and will likely retain its leading position in the years to come on account of pharmaceutical companies focusing on applications of oligonucleotides in therapeutics, research and diagnostics. Another factor helping to catalyze growth in the market in the region is the increasing occurrence of genetic disease and the subsequent thrust on developing newer and advanced drugs. The North America market is predicted to account for 34.1% share in revenue, by 2024.

As per the lead analyst of the TMR report, "The technological progress in synthetic chemistry and growing application of oligonucleotides in therapeutics and diagnostics applications will likely propel the market for oligonucleotide synthesis in the next couple of years. Further, the technological advances in synthesis of oligonucleotides provides longer and better sequence and pure oligonucleotides that can be used in a number of molecular biology applications. Different pharmaceutical and biotechnology companies are working on developing newer and advanced methods in synthetic chemistry. For instance, Integrated DNA Technologies, leader of synthesized oligonucleotides has developed various pioneered methods to synthesize oligonucleotides of extreme lengths. The company has developed oligonucleotides up to 200 base length which is used with mass spectrometry for the manufacture of mini-genes. All such activities are driving the global oligonucleotide synthesis market forward."

Report Overview and TOC https://www.transparencymarketresearch.com/oligonucleotide-synthesis-market.html

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The first successful umbilical cord blood transplantation was performed in 1988 and since then thousands of unrelated donor cord blood transplants have taken place worldwide.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Umbilical cord blood banking or cord blood banking is the practice of preserving blood from the umbilical cord for future use. Such preserved cord blood is used in medical therapies in the similar approach as that of stem cells derived from bone marrow. Umbilical cord blood banking is practiced for using the cord blood stem cells for the purpose or re-populating blood and treating various medical conditions. Umbilical cord blood is observed to be a potential source of progenitor cells, which can be used for reconstitution of tissue, organs and other functional areas.

The first successful umbilical cord blood transplantation was performed in 1988 and since then thousands of unrelated donor cord blood transplants have taken place worldwide. Cord blood transplantation is being recommended for a variety of diseases which include conditions such as sarcoma, leukemia, immune conditions, lymphoma, and even metabolic disorders. The first ever cord blood bank was established in 1991 and in the same decade several private and public cord blood banks began to be established worldwide.

Transparency Market Research projects that the global umbilical cord blood banking market, which was pegged at US$3,124.4 mn in 2016, will expand at an 11.4% CAGR from 2017 to 2025, rising to a valuation of US$8,178.1 mn in 2025.

Based on type of storage, private cord blood banks accounted for approximately 65.0% of the global market in 2016. Private cord blood banks offer cord blood storage for personal use of the donor's family with charges for storage. The average cost for processing, testing, and storage of cord blood units in private banks is around US$1,500 and an additional US$150 per year for storage continuation.

Despite such high costs, the segment of private cord blood banks is expected to remain the first choice of parents to store cord blood. Exhibiting a CAGR of 12.5% from 2017 to 2025, the segment is expected to witness a notable rise in its share in the global market by the end of the forecast period. Several factors, such as complete ownership rights preserved by the donor, flexible collection sites, and assured and secured access one's cells give private cord blood banks significant leverage over public cord blood banks, resulting in the high preference to the former despite high costs.

Geographically, the North America market for umbilical cord blood banking leads the global market, commanding more than 38.2% share in the global market in 2016. The North America market is expected to continue its strong growth in the next few years as well, chiefly owing to the rising demand for umbilical cord blood in stem cell research. Demand for cord blood banking in North America is high in the U.S., which held 83.8% market share in 2016, followed by Canada. Higher market share of the U.S. is attributed to the presence of highly established research and development infrastructure and rising investments by pharmaceutical giants in stem cell research.

Asia Pacific is expected to dominate in terms of growth rate in the global umbilical cord blood banking market over the report's forecast period. Although the region currently holds a nominal share in the global market, it exhibits enormous growth potential owing to vast improvement in health care reforms and increasing awareness of stem cell banking in select countries of Asia Pacific, such as India, Malaysia China, and Indonesia. Also, Asia Pacific is a relatively untapped regional market compared to developed regions, which is why it presents better opportunity for growth for companies.

Some of the leading players operating in the global umbilical cord blood banking market are CBR Systems, Inc., ViaCord Inc., China Cord Blood Corporation, Cord Blood America, Inc., Cryo-Cell International, Inc., Cryo-Save AG, Cordlife Group Ltd., Vita 34 AG, LifeCell, and StemCyte Inc.

Request to view table of content @ https://www.transparencymarketresearch.com/report-toc/19922

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Global Platelet-Rich Plasma (PRP) Market: Shifting Focus of Leading Players towards Emerging Economies to Influence Market’s Future, says TMR

Albany, NY -- (SBWIRE) -- 12/21/2017 -- With a larger pool of players operating domestically and a smaller bunch of international participants, the global platelet-rich plasma (PRP) market demonstrates a semi-consolidated landscape. The top five players, namely, Harvest Technologies, Arthrex Inc., Zimmer Biomet, DePuy Synthes, and Stryker Corp. accounted for more than 80% of this market in 2015. Most of these are headquartered in North America. However, their focus is likely to shift towards emerging economies across Asia Pacific in the coming years, as this region is expected to offer lucrative opportunities on account of untapped potential.

As per the research study, the global market for PRP, which was valued at US$160.0 mn in 2015, is likely to expand at a CAGR of 12.50% during the period from 2016 to 2024 and report an opportunity worth US$451.9 mn by the end of the forecast period. The P-PRP segment, which occupied more than 60% of the overall market in 2015, is expected to remain leading throughout the forecast period.

The research report has also evaluated the global market for PRP on the basis of its geographical spread. It has identified North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America as the key regional markets for PRP across the world. Supported by the increasing count of orthopedic and cosmetic surgeries, North America led the global market with a majority share in 2015. Further, the wide presence of leading market players and the high awareness level among consumers about PRP therapy and devices are likely to ensure the leadership of this regional market throughout the forecast period.

Asia Pacific is also expected to witness a healthy rise in the adoption of PRP therapies in the near future. The swiftly growing medical tourism industry, presence of well-established local players, increased base of the geriatric population, and the rising awareness regarding PRP among people are projected to boost the Asia Pacific PRP market over the forthcoming years, states the research report.

"The significant increase in the count of orthopedic patients, worldwide, is the prime factor behind the tremendous progress of the global PRP market," says a TMR analyst. As PRP therapy curtails the healing time of orthopedic or sports injuries from 4-6 months to 3-5 weeks with surgery, its demand for the treatment of orthopedic surgeries has increased remarkably and this is likely to remain so over the next few years.

The rise in cosmetic surgical procedures is another important factor that is likely to shape the future of the global PRP market. The high cost of PRP products and therapy is expected to hamper the growth of this market to some extent during the forecast period, notes the research study.

Request to view table of content @ https://www.transparencymarketresearch.com/report-toc/4021

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Transparency Market Research has announced the addition of the “Alipogene Tiparvovec Market Global Industry Analysis and Opportunity Assessment, 2016 - 2024"report to their offering.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Alipogene Tiparvovec has shown great results as a gene therapy used in the treatment of lipoprotein lipase deficiency (LPLD). LPLD is a rare condition, mostly inherited, that occurs coupled with increased accumulation of fat in blood, which can later cause severe pancreatitis. Alipogene Tiparvovec is one of the first therapeutic cures administered to LPLD patients. Prior this, patients were advised severe dietary restriction. A few others were administered with medium-chain triglycerides that held risk of pancreatitis or disease progression.

Supported by favorable initiatives from government institution, the alipogene tiparvovec has been exhibiting strong growth since the last few years. Due to the rising prevalence of lipoprotein lipase deficiency, the demand for alipogene tiparvovec is projected to accelerate further in the forthcoming years. Additionally, funding provided for the research and development surrounding alipogene tiparvovec by various international organizations will give impetus to the market.

Request Report toc @ https://www.transparencymarketresearch.com/alipogene-tiparvovec-market.html

The report presents a comprehensive overview of the various factors promoting the expansion of the global alipogene tiparvovec. It has used industry-leading analytical tools to gauge the bargaining power of buyers and suppliers, degree of competition prevailing in the market, and opportunities for new entrants. Besides this, a holistic description of the prevailing vendor landscape in the market. The profiles of the leading companies are included and the impact of strategies they adopted on the overall market operations are studied in detail.

Global Alipogene Tiparvovec Market: Trends and Opportunities The prevalence of lipoprotein lipase deficiency is around one or two person per million. It is however the most common cause of hyperchylomicronaemia, Alipogene tiparvovec has been successfully tested in three clinical studies conducted in Canada and Netherlands. The studies were conducted on a total of 27 LPLD patients. Glybera proved tolerable in all three trials with no relevant observations of any safety issues.

Data from these clinical trials revealed that administration of Glybera in a single dose has ensured long-term biological activity and reduction in chances of pancreatitis. Furthermore, interventional studies have released that alipogene tiparvovec is considerable tolerable without dose-limiting toxicity.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4469

However, side effects reported with Glybera such as leg pains, headache, hyperthermia, and tiredness often make doctors of prescribing or administering it to patients. Furthermore, Glybera is not prescribed to be used in patients suffering from muscle disease, increased risk of bleeding, or immunodeficiency. Also it is important for patients to refrain using oral contraceptives along with Glybera. This long list of dos and don'ts could hamper the market's growth to an extent.

Global Alipogene Tiparvovec Market: Regional Outlook Regionally, Asia Pacific, Europe, North America, and Rest of the World are identified as the key markets for alipogene tiparvovec. Glybera was the first gene therapy to gain approval in North America and Europe. Because LPLD is more prevalent in Canada and African countries, their demand is considerably higher across these regions.

Pre Book Full Report @ https://www.transparencymarketresearch.com/alipogene-tiparvovec-market.html?secure=NTIxNS41&type=PB

Global Alipogene Tiparvovec Market: Vendor Landscape Currently UniQure biopharma B.V. holds the market authorization of alipogene tiparvovec. Other organizations involved in the research and development of the drugs are ICON, the Clinical Trial Company Limited, International Antiviral Therapy Evaluation Center, and International Antiviral Therapy Evaluation Center.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Global Antithrombin Market: Savvy Players Focus on Research and Development for Innovative Products, says TMR

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Antithrombin Market : Segmental Highlights and Table of Content (2017 - 2025)

Global Antithrombin Market: Savvy Players Focus on Research and Development for Innovative Products, says TMR

As per estimates presented in a report by TMR, the demand global antithrombin market will rise at a CAGR of 5.2% for the forecast period of 2017 to 2025. The market for antithrombin is predicted to attract a revenue of US$704.5 mn by the end of 2025 from US$448.2 mn in 2016.

Report Overview @ https://www.transparencymarketresearch.com/antithrombin-market.html

The global protein expression technology market is segmented on the basis On Application, Geographically

Based on the application type, the antithrombin market has been segmented into: therapeutics, research and diagnostics. Each of the market segments have been extensively analyzed based on the market related factors such as increasing demand of antithrombin products worldwide, and technological advancement. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, antithrombin market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Rest of World. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides with market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, Porter's five forces analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global antithrombin market.

Request A Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4500

Summary of Table of Content
Preface
Assumptions and Research Methodology
Executive Summary
Market Dynamics
Antithrombin Market Analysis, by Application
Global Antithrombin Market Analysis, by Source
Global Antithrombin Market Analysis, by Dosage Form
Global Antithrombin Market Analysis, by Region
North America Antithrombin Market Analysis
Europe Antithrombin Market Analysis
Asia Pacific Antithrombin Market Analysis
LATAM Antithrombin Market Analysis
Rest of World Antithrombin Market Analysis
Competition Landscape

Summary of Table of Content @ https://www.transparencymarketresearch.com/report-toc/4500

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

E-Clinical Solution Software Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2014 - 2020

Albany, NY -- (SBWIRE) -- 12/21/2017 -- Transparency Market Research (TMR) has recently published a market study on the global E-clinical solution software market, estimating the market to expand at a CAGR of 13.80% during the period from 2014 to 2020 and reach a market value of US$6.8 bn by the end of the forecast period.The research report, titled "E-Clinical Solution Software Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020", states that the worldwide E-clinical solution software market stood at US$3 bn in 2014. The rising number of clinical trials has been considered as the key driving force behind the growth of this market.

The research report analyzes the worldwide E-clinical solution software market on the basis of product, mode of delivery, and end-use industry. By product type, the global market for E-clinical solution software is classified into the solutions markets for clinical trial management, clinical data management, electronic clinical outcome assessment, trial supply management, and safety solutions.

Report Overview @ https://www.transparencymarketresearch.com/e-clinical-solution-software-market.html

Based on the mode of delivery, it is categorized into the markets for web-based solution software, cloud-based solution software, and licensed enterprise solution software. The web-based e-clinical software solution market has been reporting the highest growth, whereas the cloud-based e-clinical solution software market is likely to report the fastest development among all the segments based on mode of delivery. The web-based e-clinical solution software market stood at US$2.1 bn in 2014. Analysts project it to reach a value of US$4.8 bn by the end of 2020, expanding at an estimated CAGR of 14.20% between 2014 and 2020.

The pharmaceutical industry, the healthcare sector, and chemical research organizations (CROs) are the key end users of E-clinical solution software across the globe. The pharmaceutical industry is reporting the highest demand for E-clinical solution software, owing to which this segment is likely to be the leading end user over the forecast period. On the other hand, the CROs segment is projected to post the fastest growth among all the end users in the coming years, says the report.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2548

As per the report, the global market for E-clinical solution software is divided into North America, Asia Pacific, Europe, and the Rest of the World. Among these, North America has emerged as the leading market for E-clinical solution software in the global arena. The North America E-clinical solution software market stood at US$1.7 bn in 2014. Analysts expect it to expand at a CAGR of 12.60% between 2014 and 2020 and reach a value of US$3.6 bn by the end of the forecast period. The Asia Pacific market for E-clinical solution software, however, is reported to witness the fastest growth over the forthcoming years, notes the study.

Summary of Table of Content @ https://www.transparencymarketresearch.com/report-toc/2548

The research report also presents the competitive landscape prevalent in the global E-clinical software market by analyzing the company profile of key market players. Oracle Corp., Medidata Solutions Inc., Merge Healthcare Inc., PAREXEL International Corp., ERT, BioClinica, OmniComm Systems Inc., DATATRAK International Inc., PHT Corp., and CRF Health Inc. are the major E-clinical solution software providers in the global arena, states the market study.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The global wearable medical devices market was valued at US$2.7 bn in 2014 and the opportunities in the market is expected to reach about US$10 bn by 2023. The market is projected to rise at a robust CAGR of 18.0% from 2015 to 2023.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The top five players in the wearable medical devices market accounted for a combined market share of 47.0% in 2014, which leads to some degree of consolidation in an otherwise fragmented market. Some of the leading companies are Polar Electro, Fitbit, Inc., OMRON Corporation, and Medtronic, with OMRON Corporation holding a significant revenue share of almost 11.0% in the same year. The global electronics company increasingly focuses on home healthcare devices, usually portable medical devices such as pedometers and blood pressure monitors to strengthen its shares. Another major player Fitbit, Inc., pioneers in offering wearable technology devices for tracking fitness to gain a competitive edge over others.

The presence of large number of regional players makes the wearable medical devices market intensely competitive. Several smaller players in the market strive to develop innovative products to get a strong foothold in the market, while large players are boosting their distribution chains to consolidate their markets shares across regions.

Geographically, the global wearable medical devices market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Of these, North America is the major regional market and is expected to reach a valuation of US$4.5 bn by the end of the forecast period. The substantial growth of this regional market is driven by the presence of large number of mid-sized and large companies, rapid emergence of new players, and early adopters.

Based on diagnostic device, the wearable medical devices is segmented into neuromonitoring devices, vital signs monitors, and fetal monitors and obstetrics devices. The neuromonitoring devices is further sub-segmented into electroencephalograph and electromyography. The major sub-segments of vital signs monitors are heart rate monitor, sleep monitor, activity monitor, and electrocardiograph. The electrocardiograph segment is projected to grow at a significant CAGR of 17.8% during the forecast period, primarily attributed to growing prevalence of cardiovascular diseases.

The global wearable medical devices is primarily driven by the rapidly growing demand for these devices for health monitoring and in the diagnosis of various diseases. Constant product innovations is a key factor boosting the market. The burgeoning demand of portable and high-end devices to monitor fitness among athletes and tech-savvy people is expected to fuel the wearable medical devices market. The growing prevalence world over and the increasing incidence of chronic diseases among geriatric population are anticipated to catalyze the market in the coming years. The need for real-time monitoring of medical conditions of outpatients suffering from chronic medical conditions is another crucial factor spurring the demand for wearable medical devices. In addition, the advent of cost-effective wearable medical devices that provide basic functionalities such as monitoring glucose levels and blood pressure among ailing people is expected to boost the market through the forecast period.

The use of wearable medical devices for real-time monitoring of health conditions by clinicians is another seminal factor bolstering the uptake of these devices. However, the vulnerabilities associated with hacks of wearable devices is a key concern likely to hinder the adoption to an extent. Be that as it may, several governmental regulations, such as the EU regulations, ensuring the safety and performance of medical wearable is expected to bode well for the market in the coming years. In addition, major collaborations between technology companies and medical device manufacturers are expected to create exciting opportunities for market players.

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/1733

About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The Asia perimplantation genetic diagnosis market is anticipated to exhibit a 6.8% CAGR between 2015 and 2023. The market is expected to rise to a valuation of US$28.8 mn by the end of 2023 from worth US$16.0 mn in 2014.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The competitive scenario in the Asia preimplantation genetic diagnostics market is highly intense owing to the several global and local players trying their luck in the region, states Transparency Market Research (TMR) in a research report. Pertaining to the number of service providers of preimplantation genetic diagnosis market, it is a highly fragmented one in nature. The penetration of other regional players might further intensify the level of competition in the market in the years ahead. Some of the companies operating in the market might be F. Hoffmann-La Roche, Thermo Fisher Scientific Inc., Perkin Elmer Inc., Illumina Inc., Natera Inc., and Abbott Laboratories, among many others.

Preimplantation hereditary finding for the screening of aneuploidy held the chief offer of 34.7% in the Asia PGD showcase in 2014. Liberal controls relating to this range of conclusion in most Asian nations is the central point behind the high quantities of aneuploidy screening tests embraced each year in the district. Be that as it may, PGD for single quality issue is anticipated to grow at the quicker CAGR from the period in the vicinity of 2015 and 2023. Expanded inclination of this demonstrative methodology is supported by innovative progressions and generally high precision of results. Additionally, single quality issue screening is more useful contrasted with customary pre-birth demonstrative testing in developing life, driving the market for PGD for single quality issue.

Region-wise, the Asia preimplantation genetic diagnosis market is likely to witness fruitful opportunities in the Southern Asia region. In most Asian nations where PGD is not disallowed, it is controlled by the provincial or national government. The high expenses of PGD methods are likewise a zone of massive worry for certain cost sensitive nations in the area. Consolidated with liberal administrative standards and the rising populace of high-procuring people, Southern Asia will rise as the most lucrative market for preimplantation hereditary conclusion in the following couple of years. The PGD advertise in Southern Asia is required to ascend at an ideal 7.9% CAGR from 2015 to 2023.

Growing Penchant towards Assisted Reproductive Techniques to Bolster Deployment

Rising inclination to helped regenerative methods, which include preimplantation hereditary finding as a standard game-plan for guaranteeing that the incipient organism is free of any hereditary oddities, is integral to the solid development of the Asia PGD advertise. The interest for helped regenerative systems in the locale is driven significantly because of two elements: postponed period of origination among ladies and the alarmingly rising rate of fruitlessness in the area. With rising support in the locale's workforce, countless ladies are considering their infants in late 20s to late 30s. As infertility issues and difficulties worried about imagining begin heightening as the age rises, couples in the area are progressively favoring helped conceptive systems, for example, in vitro treatment.

The rate of infertility in nations, for example, China and India has considerably expanded in the previous couple of years. Xinhua, one of China's unmistakable news offices has expressed that around 12.5% of China's populace was fruitless in 2010. In India as well, around 10% of the populace was said to be experiencing infertility in 2013. This factor is likely to be a core triggering factor for the growth of the market.

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/9989

About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The global X-ray photoelectron spectroscopy market stood at US$443.5 million in 2014 and is expected to reach US$749.8 million by the end of 2023. The market is anticipated to rise at 5.8% CAGR from 2015 to 2023.

Albany, NY -- (SBWIRE) -- 12/21/2017 -- The X-ray photoelectron spectroscopy (XPS) market is characterized by the presence of large regional players, particularly in several developed nations. Prominent players operating in the market include Thermo Fisher Scientific, ULVAC-PHI, Japan Electron Optics (JEOL) Ltd., Evans Analytical Group LLC., and Kratos Analytical Ltd. Leading companies are consolidating their presence in various emerging markets such as China, India, and Australian, notes Transparency Market Research (TMR). Top players are actively capitalizing on numerous opportunities opening up there, in a move to strengthen their shares.

Regionally, the X-ray photoelectron spectroscopy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, Asia Pacific is anticipated to rise at the leading CAGR during the forecast period. The regional market is expected to be driven by constant advancements in surface characterization methods and substantial improvements in infrastructure in developing nations.

Based on the type of analysis done with XPS, the market is segmented into elemental analysis forensic analysis, contamination analysis, and electronic density estimation. Among these, the elemental analysis is projected to rise at the leading CAGR over the forecast period. The dominance of the segment is attributed to the demand for XPS for analyzing the chemical state and electronic state various the elements.

Pharmaceutical and Medical Sectors to Witness Extensive Demand

The X-ray photoelectron spectroscopy market is primarily driven by the growing demand for technologies for analyzing the surface chemistry of materials in a number of industries including healthcare, pharmaceuticals, automotive, aerospace, semiconductors, and electronics. XPS is being increasingly used in surface characterization in order to alter or modify the properties of materials such as corrosion rates, catalytic activities, adhesive properties, and wettability. This is gaining prominence in improving the efficacy of surface engineering in these industries.

The burgeoning application of XPS technology in material researches in the medical and pharmaceutical industries is propelled by their substantial role in drug safety determination processes. The increasing application of XPS in understanding the spatial control of a variety of biomolecules and cells used in tissue engineering research is anticipated to boost the market. Furthermore, stringent regulations related to the testing of the effectiveness of the molecules used in drug discovery activities have accentuated the X-ray photoelectron spectroscopy market. The application of XPS as surface characterization tools in the healthcare industry is gaining traction in the healthcare industry, thereby catalyzing the market growth.

However, the lack of alternative spectroscopic methods and the paucity of expertise in using XPS techniques are crucial factors likely to impede the market to an extent. Nevertheless, the growing popularity of X-ray photoelectron spectroscopy methods in forensic analysis is expected to create a plethora of exciting opportunities for several market players. Furthermore, recent advancements in surface engineering technologies have improved the efficacy of the XPS techniques leading to the advent of methods with rapid turnaround times. The demand for novel forensic tools is anticipated to open up lucrative growth avenues in the coming years.

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/9194

About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

As the need for optimum healthcare services is seeing a continuous rise with the augmenting percentage of worldwide population, the global market for healthcare supplies is anticipated to grow at a stirring rate.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- The international healthcare supplies market is currently riding on the demand for early detection of diseases for effective treatment and introduction of sophisticated medical devices by the leading firms in the industry. Hospital acquired infections (HAIs) are a serious issues in the healthcare industry and have increased the need for the implementation of top-end healthcare supplies even more.

Experienced analysts suggest that the world healthcare supplies market could be segmented according to product, application, and end use. Different segments of the market are closely analyzed to provide information on the largest and fastest segments under each category and their market share.

This report published by our expert panel of analysts have meticulously examined the important aspects of the global healthcare supplies market, viz. growth factors, restraints, trending opportunities, and competitive landscape. Buyers of the publication can illuminate their each step in the business with the epoch-making guidelines offered to ensure a promising turnaround.

Request Report TOC @ https://www.transparencymarketresearch.com/healthcare-supplies-market.html

Global Healthcare Supplies Market: Trends and Opportunities

As the need for optimum healthcare services is seeing a continuous rise with the augmenting percentage of worldwide population, the global market for healthcare supplies is anticipated to grow at a stirring rate. Presently, there is a dramatic growth witnessed on the part of home healthcare facilities, which is expected to offer a strong boost to the world healthcare supplies market. With an intensifying level of incidences of different disorders and medical conditions, the demand for advanced healthcare supplies will likely be on the higher side. Additionally, the quickly rising aging population has multiplied the magnitude of patient care activity.

The cost-sensitiveness exhibited by healthcare centers and hospitals with respect to the purchase of quality healthcare products is foretold to slightly dwindle the growth of the international healthcare supplies market. The stiff regulations prescribed under private and public health insurances related to the fees of medical procedures are the main reason for the end users becoming cost sensitive. However, the international market is predicted to take hold of an impressive degree of prominence in the medical devices sector on the back of product innovation. In this regard, the market is foreseen to be positively influenced during the course of the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=383

Global Healthcare Supplies Market: Geographical Analysis

On the geographic terms, the worldwide healthcare supplies market is prognosticated to announce North America as a key share holder followed by Asia Pacific. The swelling prevalence of obesity, hypertension, diabetes, cardiovascular diseases, and other lifestyle related health conditions could provide a lucrative rostrum for North America to display its dominance in the global market. Other factors such as frequent medical conferences, consolidated hospitals, choice initiatives by governments, and occupancy of significant market players are envisaged to further push the market growth.

Since the developing countries can furnish a promising podium for the players to rake in a thumping demand, the Asia Pacific market could steer its boat in just the right direction. Also forecasted to demonstrate a faster growth, Asia Pacific can count its rise on the high level of population, prevailing gap between demand and supply, and healthcare reforms making a steady headway.

Global Healthcare Supplies Market: Competitive Landscape

Amongst the crucial players witnessing a breakthrough in their healthcare supplies business, C.R. Bard Inc., Covidien Plc, Johnson & Johnson, Invacare Corporation, and Bayer AG have pronounced their presence in the world healthcare supplies market. With a view to generate a stupendous share in the market, these companies are anticipated to consider product enhancements and other key business strategies. The study presented here digs deep into the competitive scenario while taking into account the impact of top players and their critical strategies sustaining them in the market.

Pre Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=383

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The disinfectant equipments market can be broadly segregated into reusable and non-reusable equipment.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- The research report offers deep understanding of the disinfectant equipments market structure. It investigates different aspects, and explains quantitative as well as qualitative analysis patterns. It divides the market on the basis of different logical parameters and examines each segment and sub-segment in the overall industry. The factors that drive as well as restrain the growth of the industry have been described, helping companies take important steps for their business futures. The report explains the importance of sterilization and disinfectant methods and chemicals for the control of infections in healthcare facilities including hospitals, laboratories, and clinics. It utilizes all regulatory discretions that aim to control the usage of chemicals in the disinfectant equipments market.

The research report uses Porter's five force analysis to submit a broad range of easy-to-use market analysis. It goes ahead to perform a value chain assessment along with a SWOT analysis to help you stay in touch with the projected chances and competitive trends in the mobile entertainment market.

Request Report TOC @ https://www.transparencymarketresearch.com/disinfectant-equipments-market.html

Overview

The disinfectant equipments market can be broadly segregated into reusable and non-reusable equipment. Usually, reusable equipment is the kind that has to enter a patient's sterile tissue or vascular system. Sterilization involves the use of disinfecting chemicals, physical or chemical processes that destroy all microbial and bacterial life on an object or a surface. This also includes highly resistant endospores. A hospital utilizes the typical sterilization methods of steam autoclaving of moist heat, dry heat, and ethylene oxide gas. Apart from the physical methods, hospitals also use chemical germicides that can be used to disinfect heat-sensitive and water-sensitive equipment.

The key market driver for disinfectant equipment is a country's population. More number of people implies an increased use of cleaning agents, especially in places of medical importance. China will therefore have the largest patient base, and provide the largest buyer's market for disinfectant equipment. Second in line is India with a population of nearly 1.2 billion. The provision of disinfectants is of utmost importance in the healthcare industry, making the disinfectant equipment market one of the leading healthcare markets available.

The key restraints for the disinfectant equipment market are government regulations that restrict or ban the use of certain chemicals for use, and the limitations on production of particular chemicals that are in high demand. The top categories in the disinfectant equipment market are based on their type, and include physical sterilization, radiation sterilization, and chemical sterilization.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=353

Companies mentioned

The biggest names in the disinfectant equipments market are: Becton, 3M Healthcare, Getinge AB, Kimberly-Clark Corporation, Cardinal Health Inc., Dickinson and Company, Molnlycke Health Care AB, STERIS Corporation, Advanced Sterilization Products Services Inc., and B. Braun Melsungen AG.

Pre Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=353

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The global market for needle-free drug delivery devices has been registering a remarkable rise over the last few years, thanks to the growing demand for painless delivery of medications across the world.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- The nature of the business landscape is highly consolidated with the alliances between the companies operating in the needle-free delivery devices market increasing, states Transparency Market Research (TMR) in a research report. The leading three companies, namely, Antares Pharma Inc., 3M, and Zogenix collectively held a share of over 60% in the global market for needle free drug delivery in 2014. Apart from partnerships, acquisitions, and mergers, the core vendors are now focusing on the introduction of advanced devices on the basis of novel technologies for strengthening their position in the market for the long run and staying competitive as well. Going forward, the huge swath of in fact propelled gadgets - in the pipeline at show - will additionally strengthen the opposition in the overall market for sans needle sedate conveyance gadgets sooner rather than later.

According to a TMR analyst, "The global needle free drug delivery market is anticipated to rise at a 9.90% CAGR from 2015 to 2023. In 2014, the market was worth US$5.4 bn and is likely to touch a valuation of US$13 bn by the end of 2023." In terms of application, the market can be segmented into pain management, pediatric injections, vaccine delivery, and insulin delivery. The demand for needle free drug delivery was at peak in the segment of insulin delivery and is likely to remain the same over the next couple of years.

Report Overview @ https://www.transparencymarketresearch.com/needle-free-delivery-devices-market.html

Developing Preference for Painless Delivery of Medicines to Bolster Sales of Needle-Free Drug Delivery Devices

The developing inclination for productive and easy conveyance of medications is driving the drug delivery market towards sans needle infusion systems. As these systems make utilization of a technology that is liquid drug delivery based and works viably with effectively accessible medication definitions, the advancement costs on these items are low. This has empowered various medicinal gadgets producers to put resources into needle free drug delivery devices, thus pushing the growth of the market.

What's more, the expanding need to avoid needle-stick wounds is probably going to empower the reception of needle free drug delivery devices fundamentally amid the conjecture time frame. The rising commonness of irresistible sicknesses, for instance, hepatitis, dengue, and AIDS, and different cardiovascular and neurological infections, which require ceaseless organization of medications, is additionally anticipated to make generous interest for these gadgets throughout the following couple of years. Needle free drug delivery devices are generally used for the organization of insulin in the human body. The insulin conveyance section has been driving the application portion since the most recent couple of years and is anticipated to stay predominant over the coming years.

Developing Regions to Provide ample Opportunities

Examiners anticipate North America to hold its predominance sooner rather than later but with a lessened piece of the overall industry. Asia Pacific, on the other side, is anticipated to rise as the speediest rising local market for needle free drug delivery in the coming years.

The developing pervasiveness of unending cardiovascular and neurological infections, the infrastructural advancement in the restorative and human services industry, and the expanding center of driving players in this area due to neglected medicinal need are required to help the reception of these gadgets in Asia Pacific extensively soon. These gadgets are additionally expected to encounter a solid ascent in their demand in the Middle East and Africa and Latin America because of the improvement of the human services situation in these areas throughout the following couple of years.

Request To Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=447

Summary of Table of Content
1. Preface
2. Executive Summary
3. Needle Free Drug Delivery Devices Market - Industry Analysis
4. Market Segmentation - By Technology
5. Market Segmentation - By Application
6. Market Segmentation - By Geography
7. Recommendations
8. Company Profiles

Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=447

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The rising use of collagen in medical devices and drug delivery systems, increased preference for minimally invasive technologies, and the effectiveness in wound healing are expected to be some of the key factors driving the global demand for collagen in the coming years.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- Transparency Market Research in one of its new research reports, says the global collagen market is largely held by a few top players that offer myriad product offerings for most applications of collagen. The small number of global players for niche application segments and a considerable increase in the incidence of chronic diseases such as diabetes and cancer will aid collagen companies to thrive in their specialty segment.

The market, however, features immense fragmentation, especially in regional pockets wherein small players give tough competition to large players with competitively priced products.

Collagen Matrix Inc., for example, has gained a significant presence in the market due to operations across some key application areas. Some other key vendors such as Nippi Inc. Botiss biomaterials GmbH, Baotou Dongbao Bio-tech Co. Ltd., and Collagen Solutions plc have product or service offerings that are specific to one or two application areas.

Report Overview @ https://www.transparencymarketresearch.com/collagen-market.html

A report by Transparency Market Research projects the global collagen market to rise at a CAGR of 9.4% for the forecast period between 2015 and 2023. At this pace, the market which was evaluated at US$4.13 bn in 2014 will become worth US$9.37 bn the end of 2023.

Bovine and porcine sources are presently the leading sources of collagen that are used across a number of applications. Bovine collagen accounted for 30 kilo tons of collagen in the overall market in 2014. Porcine collagen accounted for 27.4 kilo tons in the global collagen market in the same year.

However, bovine and porcine collagen sources are expected to witness slight decline over the forecast period due to cultural beliefs and disease transmission risks. Marine collagen, among all, is considered to be the safest and is thus expected to witness leading demand over the forthcoming years. The segment of marine collagen is expected to expand at a CAGR of 11.6% from 2015 to 2023 vis-a-vis volume.

North America and Europe are the key regional segments for collagen owing to a high level of awareness about the benefits of collagen and collagen products.

Growing Demand for Minimally Invasive Treatment Modalities Drives Market

The key factor stoking growth of the collagen market is the increasing preference for minimally invasive or completely noninvasive surgeries worldwide. The increasing demand for collagen products in wound healing applications on account of their easy availability and biodegradability is also a key growth driver for the global collagen market.

The rising use of collagen in wound healing products has led leading pharmaceutical and biotechnology companies to make hefty investments for R&D pursuits. These product development activities are aimed at enhancing the efficiency of existing collagen products. In order to increase the commercialization of newer collagen-based products such as drug delivery systems, companies in the market are striving to tap vast business opportunities across developing regions.

Rising Geriatric Population to Catapult Demand for Collagen Products in Asia Pacific

The rising number of individuals above the age of 60 years in Asia Pacific is expected to be key factor stoking growth of collagen market. As per a 2015 report by The United Nations, two-thirds of the world's elderly population reside in developing regions and their numbers are increasing at an expeditious rate. Studies reveal that 56% of the world's elderly population resided in Asia alone in 2015; this number is expected to increase to 60% by 2030. The growing geriatric population in the region is expected to account for considerable demand for collagen products in the upcoming years.

Request To Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10460

Summary of Table of Content

1. Preface
2. Executive Summary
3. Industry Analysis: Global Collagen Market
4. Global Collagen Market Segmentation – by Sources
5. Global Collagen Market Segmentation – by Application
6. Global Collagen Market Segmentation- by Geography
7. Recommendations
8. Company Profiles

Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=10460

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The number of patients suffering from opioid induced constipation is increasing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from OIC, according to the American Academy of Pain Medicine.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- Takeda Pharmaceuticals Company, Ltd., with its approved drug Amitiza, holds a majority share in the global market for opioid induced constipation treatment. In 2014 the top three players - Takeda, Valeant Pharmaceuticals International, Ltd., and Boehringer Ingelheim – operated on a collective share of 91.8% of the global market.

This is a highly consolidated market but with a large scope for the prominent players to penetrate regions other than North America.

ransparency Market Research's recent publication reveals the possibilities that players in the global market for opioid induced constipation treatment can take up to improve their global standing in the market. This includes reaching out to the emerging economies and gain shares from a currently untapped market.

The global market for opioid induced constipation treatment is expected to progress at a highly positive CAGR of 31.2% within a forecast period from 2015 to 2023 with respect to revenue. By the end of 2016, this market is expected to generate US$731.2 mn, which is projected to reach US$4.81 bn by the end of 2023.

Chloride channel activators are the more popular drug class among all opioid induced constipation treatments currently available. Over time, PAMORAs are expected to overtake them owing to a large number of pipeline drugs close to approval. By the end of 2023, PAMORAs are expected to generate a revenue of US$2.41 bn.

Report Overview @ https://www.transparencymarketresearch.com/opioidinduced-constipation-treatment-market.html

North America to Continue Generating Leading Demand for OIC Treatments

North America is expected to continue dominating the demand for opioid induced constipation treatments till 2023, owing to a majority consumption of opioids. The American Society of Interventional Pain Physicians has stated that in 2013, the U.S. alone was responsible for nearly 80% of the global consumption of opioids. Key reasons for this high consumption include the legal acceptance of opioids for pain treatment by the U.S. FDA, and the high awareness consumption level of opioids for the long term treatment of chronic pain.

By the end of 2023, it is predicted that North America will generate US$4.05 bn in revenue for the providers of opioid induced constipation treatments.

A secondary reason for this high volume of consumption is also related to the extremely low awareness rates of available opioid induced constipation treatments in other regions.

Multiple OIC Drug Approvals Imminent, Demand Expected to Rise Accordingly

"Most certainly the leading driver for the growth in demand of opioid induced constipation treatments is the awaited approval of several drugs that are in the pipeline. Naldemedine is one of the stronger contenders which is expected to be released before the end of 2016," states a TMR analyst.

Furthermore, the increasing development rate of peripheral mu-opioid receptors is expected to generate a giant boost to the preference of OIC-specific treatments. PAMORAs allow for the effective treatment of OIC without interfering in the opioids action on the patient's pain.

Request To Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

Standard Laxatives Still Considered a Challenge to OIC Treatments

One of the greater restraints currently acting on the demand for opioid induced constipation treatments is the widespread consideration of standard laxatives for countering OIC. The primary reason for this is the high disparity between the pricing of standard laxatives and targeted OIC drugs.

At the same time, the relatively under-researched position of opioid induced constipation treatments needs to be worked on. Most of these drugs are showing several adverse effects, including nausea as well as increasing the risk of heart problems and strokes.

"A way out for opioid induced constipation treatments is to improve the scope of development to reduce their side effects and improve efficacy. There is currently a giant untapped market for opioid induced constipation treatments across the world, and investing more in marketing and R&D will definitely help players penetrate it," adds the analyst.

Summary of Table of Content

1. Preface
2. Executive Summary
3. Opioid Induced Constipation Treatment Market - Industry Analysis
4. Market Segmentation - By Dosage Form of the Drug
5. Market Segmentation - By Drug Class
6. Pipeline Analysis
7. Market Segmentation - By Geography
8. Recommendations
9. Company Profiles

Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=6862

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Aesthetic services are increasingly finding appeal and usage across a vast number of areas such as skin pigmentation correction, scar treatment, acne treatment, psoriasis treatment, and eczema treatment.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- Over the past few years, the market for aesthetic services has witnessed a surge in research activities. Vast developments in the area has increased the overall knowledge of the mankind about bioengineered products capable of treating naturally occurring superficial skin imperfections or scars resulting from wounds, acne, burns, and other issues.

With the rapid rise in world's aging population and an increased consciousness regarding one's aesthetic appeal, the demand for processes capable of augmenting soft tissue and improving a number of imperfections of the skin has also significantly increased. Aesthetic services present an efficacious solution in this area by providing dramatic improvements for a number of skin conditions without surgical procedures.

Aesthetic services are increasingly finding appeal and usage across a vast number of areas such as skin pigmentation correction, scar treatment, acne treatment, psoriasis treatment, and eczema treatment. The significantly lower time required to undertake non-invasive aesthetic procedures along with the use of bioengineered products for the same have increased the interest of the global population in these procedures.

The report provides an extensive overview of the market by segmenting it on the basis of criteria such as type of implant, procedure, and geography. On the basis of the type of implant, the market has been segmented into semi-solid gel implants, silicone implants, and saline implants. On the basis of procedures, the market has been segmented into cosmetic procedures and reconstructive procedures.

The segment of cosmetic procedures is further segmented into surgical and non-surgical cosmetic procedures. The common types of surgical cosmetic procedures undertaken across the globe include body contouring procedures such as liposuction and tummy tuck, facial contouring procedures such as cheek/chin enhancement and rhinoplasty, and facial rejuvenation procedures such as eyebrow lift, eyelid lift, and facelift. Common types of non-surgical cosmetic procedures undertaken across the globe include microdermabrasion, botox, and laser treatment. Common types of reconstructive procedures include burn repair surgery, breast reconstruction, tissue expansion, and plastic surgery.

From a geographical perspective, the report examines the market for aesthetic services for regions such as Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. Of these, North America holds the dominant position on account of the thriving market for aesthetic services in the U.S., which individually accounts for a massive share in the global market. High demand for non-surgical aesthetic procedures such as cosmetic enhancements, scar reduction and non-laser tattoo reversals are the key growth drivers of the aesthetic services market in the U.S.

Countries in regions such as Latin America and Asia Pacific are also increasingly becoming the chief destinations for aesthetic procedures. In South Korea, over 980,000 aesthetic procedures were undertaken over the period between 2014 and 2015. Countries such as India and China are also witnessing a rapid rise in the number of corrective procedures and cosmetic enhancements, riding on the back of increased consciousness regarding one's aesthetic appeal and rising disposable incomes to spend on these costly procedures.

It has been observed that the vendor landscape of the global market for aesthetic services features a highly competitive nature and presents high threats to new entrants. Some of the key vendors operating in the market are Human Med AG, Alcon Inc., Biosil Ltd., Cynosure Inc., Genzyme Corporation, Allergen Inc., and Lumentis Ltd.

The report presents an analytical overview of the competitive landscape of the market by furnishing details such as finances, product portfolio, geographical presence, involvement in activities such as mergers and acquisitions, and contribution to the global market through technological advancements for some of these leading players. Detailed SWOT analysis of the companies profiled in the report is also included to allow the reader a clear understanding of the level of competitiveness prevalent in the market.

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12947

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The increasing acknowledgment of the limitations of conventional localization methods identified by surgeons has increased the demand for alternative techniques of breast lesion localization.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- According to the World Cancer Research Fund International, breast cancer is the most common cancer in women, with an estimated 1.7 million new cases diagnosed in 2012. The highest incidence of breast cancer was in North America and Oceania. The incidence of breast cancer in North America was estimated at 80 per 100,000 individuals in Canada and around 92 per 100,000 in the U.S.

This alarming rise in the incidence of breast cancer has resulted in an increasing awareness about the disease among women and a rise in the number of screening and imaging techniques in the market. Early detection of the malignancy of palpable and non-palpable breast lesions can result in effective and timely treatment of various breast abnormalities. This is one of the major factors driving the global breast lesion guidance systems market.

The report on the breast lesion guidance systems market evaluates the overall performance of the global market and determines its various driving forces. The key challenges that lie ahead and recommendations by industry experts have also been included to give clients a well-rounded assessment of the breast lesion guidance systems market.

The increasing acknowledgment of the limitations of conventional localization methods identified by surgeons has increased the demand for alternative techniques of breast lesion localization. Technical challenges pertaining to excision and same-day wire placement have led to the development of advanced breast lesion guidance systems. The favorable reimbursement scenario for breast cancer treatment in several developed countries, the increase in the number of breast cancer surgeries, and the promising ongoing research in the field have also contributed to the growth of the breast lesion guidance systems market.

However, regulatory approval procedures are immensely lengthy and complex due to the risks associated with several breast lesion localization devices. This is likely to hamper the growth of the global market. Success in eliminating these risks and producing safer localization devices is thus a major opportunity for players operating in the global breast lesion guidance systems market.

The most widely used breast lesion guidance systems include wire-guided localization (WGL), magnetic tracers, electromagnetic reflectors, and radioisotope localization methods such as radio-guided occult lesion localization (ROLL) and radioactive seed localization (RSL). WGL involves the insertion of a wire to the center of the lesion. The ROLL method is a new technique for the localization and removal of non-palpable lesions. It involves intratumoral insertion of a radioactive tracer. In the RSL technique, an iodine seed is implanted in the center of the tumor.

There have been several studies and trials comparing and reviewing the effectiveness of various breast lesion guidance systems. Cochrane, an England-based non-profit, non-governmental firm dedicated to medical research and reviews, conducted a major study in March 2015. The organization studied the performance of wire-guided localization, the most widely used and conventional approach for the surgical removal of non-palpable breast lesions, against modern alternatives such as ROLL and RSL.

The study found that people who opted for ROLL and WGL treatment presented similar results with regard to localization and removal of the lump. The post-operative complication rates of both methods were also similar. However, compared to WGL, ROLL treatment had lower re-intervention rates and resulted in slightly fewer positive tumor margins. In terms of successful location of the lesion, WGL was found to be superior to RSL. However, in terms of the successful removal of the lump, both techniques were found to be equally effective. Compared to WGL, RSL resulted in fewer positive tumor margins.

The results of the Cochrane study revealed that WGL continues to be a safe and tested breast lesion localization method, considering the statistical insignificance of the increase in effectiveness brought about by new alternatives. At the same time, RSL and ROLL have also been shown to be equally reliable and can be offered as a comparable alternative for WGL, should WGL be difficult to perform on a patient.

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12656

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

The genetic and other biological data repository maintained by biobanks help researchers to understand the human trait associated diseases and disorders, and also the impact of environment and genetic variations on cell lines and human health.

Albany, NY -- (SBWIRE) -- 12/20/2017 -- Biobanks are kind of repositories which store the biological samples for research and educational purpose. The samples are collected form general public based on various factors such as ethnicity, age, gender, lifestyle and geography. Biobanks collect the samples in various forms such as tissues, saliva, blood, etc. A purified genomic database is maintained in these biobanks, this data is significant in research and study purpose for understanding the environmental impacts and mutations, and diseases and disorders derived from them. The samples are stored in groups of specific traits to ease their application in research purposes. The samples are collected from donors after their consensus and most of the biobanks follow the practice of donor's ownership and his consensus on use of his/her sample for any further research purpose by private entity or public organization. Biobanks play a vital role in research and development is healthcare industry.

The genetic and other biological data repository maintained by biobanks help researchers to understand the human trait associated diseases and disorders, and also the impact of environment and genetic variations on cell lines and human health. These biobanks provide extensive data based on these factors and on the basis of other demographical traits, which is expected to grow the human biobanking ownership market. The biobanks offer database of cross border population which makes its users time saving and effective resource, which is expected to increase uptake for biobanking services across the globe.

However, high cost associated with human biobanks, as the genome sequencing is costly and tedious process, the human biobanking ownership market is expected to restrain the growth across the globe. Also stringent laws and regulations in biobanking and concern over the security and privacy of human biobanks across globe is another factor expected to bolster the growth for human biobanking ownership market. In the near future, the global human biobanking ownership market is expected to be governed by laws to protect the privacy of gene donors and establish their rights. For example, in Estonia, the Human Genes Research Act passed in 1999 provides donors full authority over who can access their data and establishes anonymity in clinical research. Such laws will help in the growth of the global human biobanking ownership market.

Based on the operator of the biobank, the human biobanks can be segmented in to academic & research Institutes, pharmaceutical and biotech industry, hospitals, and stand-alone biobanks. These biobanks serve various purposes such as diagnostics, forensic, organ transplantation, research, and others. By the ownership type the biobanks can be privately funded and operated, publically funded and operated, and public-private partnership funded and operated. Some of the Government agencies promote biobanks, so as to create database of population to support in strengthening the healthcare infrastructure.

Geographically, global human biobanking ownership market is segmented in four major regions such as North America, Europe, Asia Pacific and Rest of the World. Asia Pacific has been driving the global market growth owing to the rapid growth of the private biobanks and clinical research organizations in the region. Demand witnessed in North America and Europe is also significantly aiding the growth of the market. In Europe, countries such as Estonia are focusing on collecting the DNA of every citizen in order to enrich their national biobank. In Estonia, the national biobank program started in 2000 by collecting DNA samples from a quarter of the country's population. While these DNA samples are mostly used for clinical research, the government is planning to use this data to build a robust health care infrastructure by offering personalized care. The Government of Estonia has already started developing a system to make this genetic data available to citizens and doctors.

The major players operating in the market include ProMedDx, Affymetrix Inc., Abbott Laboratories, Acorda Therapeutics, Alpha Cord Inc., Autogen Inc., Biobank Ireland Trust, BioCision, Biokryo GmbH, BioLife Solutions Inc., Biomatrica Inc., BioStorage Technologies Inc., Cells4Life Ltd., Cesca Therapeutics Inc., China Cord Blood Corporation, Core Dynamics Inc., Cryo Bio System, and Sanford Health among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12491

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm